Background and activities
Magnus Kringstad Olsen is a PhD Candidate in the Research Group of Experimental Surgery and Pharmacology at the Department of Cancer Research and Molecular Medicine, Faculty of Medicine, NTNU under supervision of Professor Duan Chen and Dr. Chun-Mei Zhao. In addition, he works as the administrative assistant of the Gastrointestinal Section at the International Union of Basic and Clinical Pharmacology. His main research is on translational medicine, obesity and diabetes.
PhD Candidate in molecular medicine – still ongoing (set to finish in 2017)
Master Degree (MSc) in molecular medicine from the Norwegian University of Science and Technology (NTNU) (2014)
Master Degree in (MSc) in molecular medicine from University of California, San Diego (2013)
Bachelor Degree (BSc) in molecular medicine & biochemistry from University of Essex (2011)
My main area of research is obesity and diabetes. The prevalence of obesity have increased rapidly for several decades, and are reaching epidemic and even pandemic proportions, hence new minimally invasive treatments are long overdue. The way we do research is by something called translational medicine. Translational medicine is a “bench-to-bedside” approach where medical improvements, being surgery or other treatments, are being implemented into the community. For the treatment of obesity I mainly work on Botox-injections in the stomach, and various restriction-regiments to reduce body weight in diet-induced obese rats. It has been well-documented that obese patients that are diagnosed with type II diabetes, that undergo bariatric surgery experience an improvement of the diabetes before they see reductions in body weight. In close collaborations with a group at University of Oxford, we investigate why we see this improvement and if these improvements can be potentially new treatments for people with type I and II diabetes.
Scientific, academic and artistic work
Displaying a selection of activities. See all publications in the database
- (2017) Time-restricted feeding on weekdays restricts weight gain: A study using rat models of high-fat diet-induced obesity. Physiology and Behavior. vol. 173.
- (2016) A Potential New Regimen (“Tricyclie”) for Treatment of Gastric Cancer: Targeting Glutamine-Dependent Wnt/β-Catenin-mTOR Signaling. Gastroenterology. vol. 150 (4).
- (2016) Intragastric Injection of Botulinum Toxin a to Treat Obesity: Mechanism of Action and a Randomized, Double-Blind, Placebo-Controlled Phase II Trial With Open-Label Extension Study. Gastroenterology. vol. 150 (4).
- (2016) Steady-state energy balance in animal models of obesity and weight loss. Scandinavian Journal of Gastroenterology. vol. 52 (4).
- (2016) PYY-Dependent Restoration of Impaired Insulin and Glucagon Secretion in Type 2 Diabetes following Roux-En-Y Gastric Bypass Surgery. Cell reports. vol. 15 (5).
- (2016) Roux-En-Y Gastric Bypass Surgery Restores Impaired Islet Architecture and Function in Type-2 Diabetes by Elevation of Plasma PYY. Gastroenterology. vol. 150 (4).
- (2015) Comparison of different surgical procedures in animal models for a better consideration of personalized bariatric surgery. Gastroenterology. vol. 148 (4).
- (2014) Preclinical Trial of Gastric Injection of Botulinum Toxin Type A as Weight-Loss-Surgery. Gastroenterology. vol. 146 (5).
- (2015) Comparison of different surgical procedures in animal models for a better consideration of personalized bariatric surgery. DDW 2015 . DDW 2015; Washington DC,. 2015-05-16 - 2015-05-18.
- (2014) Preclinical Trial of Gastric Injection of Botulinum Toxin Type A as Weight-Loss-Surgery. Digestive Disease Week 2014 ; Chicago. 2014-05-03 - 2014-05-06.
- (2014) The role of vagus nerve in the brain-gut axis: a target for obesity treatment. WCP2014 . 17th World Congress of Basic & Clinical Pharmacology; Cape Town. 2014-07-13 - 2017-07-18.